Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral poliovirus vaccine (GSK)
- Development stage
- Unknown
- Lead developer
- Panacea Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Bivalent oral poliovirus vaccine (bOPV) is a live-attenuated vaccine containing Sabin strains of poliovirus types 1 and 3. It was developed as part of the Global Polio Eradication Initiative (GPEI) to replace trivalent OPV (tOPV) following the eradication of wild poliovirus type 2, thereby reducing the risk of vaccine-derived poliovirus type 2 (VDPV2) outbreaks. Administered orally, bOPV induces both systemic IgG and local mucosal IgA immunity in the intestinal tract, which is critical for preventing both paralytic disease and the transmission of the virus. It is widely used in routine immunization and mass vaccination campaigns, often in conjunction with inactivated poliovirus vaccine (IPV) to ensure comprehensive protection against all three poliovirus serotypes.
- Brand names
- BiopolioPolio Sabin One and Three
- Other names
- bivalent Sabin oral poliovirus vaccineoral poliovirus vaccine bivalent types 1 and 3
02
Targets
Poliovirus type 1 capsid protein
Beyond the preview
Go deeper on bivalent oral poliovirus vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral poliovirus vaccine (GSK).